Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)
  7. Department of Pathology and Laboratory Medicine (415)
  8. Gastrointestinal Oncology Service (386)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2131)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (92)
  5. Editorial (84)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (129)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (855)
  3. JNCI: Journal of the National Cancer Institute (492)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (140)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4676)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical outcomes by sex with atezolizumab (atezo) monotherapy in patients (pts) with locally advanced/metastatic urothelial carcinoma (mUC)
    Meeting Abstract

    Hoffman-Censits, J.; Rosenberg, J. E.; van Der Heijden, M.; Dreicer, R.; Perez Gracia, J. L.; Petrylak, D. P.; Retz, M. M.; Sabbatini, R.; Naglieri, E.; Caserta, C.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Association between depth of response and overall survival: Exploratory analysis in patients with previously untreated advanced renal cell carcinoma (aRCC) in CheckMate 214
    Meeting Abstract

    Grünwald, V.; Choueiri, T. K.; Rini, B. I.; Powles, T.; George, S.; Grimm, M. O.; McHenry, M. B.; Maurer, M.; Motzer, R. J.; Hammers, H. J.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Lenvatinib (LEN) and pembrolizumab (PEMBRO) in advanced endometrial cancer (EC)
    Meeting Abstract

    Makker, V.; Taylor, M. H.; Aghajanian, C.; Oaknin, A.; Mier, J.; Cohn, A. L.; Romeo Marin, M.; Bratos Lorenzo, R.; Brose, M. S.; DiSimone, C.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Time to second progression (PFS2) and second subsequent therapy (TSST) for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) treated with maintenance (mt) olaparib (ola): Phase III SOLO1 trial
    Meeting Abstract

    Oaknin, A.; Moore, K.; Colombo, N.; Scambia, G.; Kim, B. G.; Friedlander, M.; Lisyanskaya, A.; Floquet, A.; Leary, A.; Sonke, G. S.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • A phase I study of AMG 160, a half-life extended bispecific T cell engager (HLE BiTE) immuno-oncology therapy targeting PSMA, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Tran, B.; Kouros-Mehr, H.; Fermin, A.; Horvath, L.; Roncolato, F.; Rettig, M.; Dorff, T.; Tagawa, S. T.; Subudhi, S. K.; Antonarakis, E. S.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • EV-103: Initial results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma
    Meeting Abstract

    Hoimes, C. J.; Rosenberg, J. E.; Srinivas, S.; Petrylak, D. P.; Milowsky, M.; Merchan, J. R.; Bilen, M. A.; Gupta, S.; Carret, A. S.; Yuan, N.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Redefining the IGCCCG classification in advanced non-seminoma
    Meeting Abstract

    Gillessen, S.; Collette, L.; Daugaard, G.; de Wit, R.; Tryakin, A.; Albany, C.; Stahl, O.; Fizazi, K.; Gietema, J. A.; De Giorgi, U. F. F.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Efficacy and biomarker analysis of patients (pts) with advanced renal cell carcinoma (aRCC) with sarcomatoid histology (sRCC): Subgroup analysis from the phase III JAVELIN renal 101 trial of first-line avelumab plus axitinib (A + Ax) vs sunitinib (S)
    Meeting Abstract

    Choueiri, T. K.; Larkin, J. M. G.; Pal, S. K.; Motzer, R. J.; Venugopal, B.; Alekseev, B. Y.; Miyake, H.; Gravis, G.; Bilen, M. A.; Chudnovsky, A.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • POLO: Time to treatment discontinuation and subsequent therapies following maintenance olaparib for patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC)
    Meeting Abstract

    Van Cutsem, E.; Golan, T.; Hammel, P.; Reni, M.; Macarulla, T.; Hall, M. J.; Park, J. O.; Hochhauser, D.; Arnold, D.; Oh, D. Y.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Preliminary safety and pharmacokinetics of a new lysosomotropic oral agent, GNS561, in a first-in-human study in advanced primary liver cancer patients
    Meeting Abstract

    Awada, A. H.; Harding, J. J.; Kotecki, N.; Aftimos, P. G.; Decaens, T.; Dreyer, C.; Ansaldi, C.; Rachid, M.; Serdjebi, C.; Halfon, P.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save